Why NuCana (NCNA) Shares Are Trading Lower
Benzinga (Thu, 28-Mar 11:41 AM ET)
Truist Financial Sticks to Its Buy Rating for Nucana (NCNA)
TipRanks (Thu, 28-Mar 8:16 AM ET)
NuCana plc Announces Reverse ADS Split
TipRanks (Wed, 27-Mar 5:27 PM ET)
NuCana announces plan to implement ADS ratio change
Seeking Alpha News (Wed, 27-Mar 4:37 PM ET)
NuCana Announces Plan to Implement ADS Ratio Change
Globe Newswire (Wed, 27-Mar 4:30 PM ET)
Nucana (NCNA) Receives a Hold from TD Cowen
TipRanks (Sun, 24-Mar 8:16 PM ET)
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
Globe Newswire (Wed, 20-Mar 4:01 PM ET)
NuCana to Present at TD Cowen's 44th Annual Health Care Conference
Globe Newswire (Tue, 27-Feb 8:00 AM ET)
NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Globe Newswire (Tue, 6-Feb 8:00 AM ET)
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Nucana PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol NCNA.
As of March 28, 2024, NCNA stock price declined to $0.26 with 677,906 million shares trading.
NCNA has a beta of -1.00, meaning it tends to be less sensitive to market movements. NCNA has a correlation of 0.02 to the broad based SPY ETF.
NCNA has a market cap of $13.31 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, NCNA stock traded as high as $5.12 and as low as $.23.
NCNA has underperformed the market in the last year with a price return of -67.6% while the SPY ETF gained +33.7%. NCNA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.3% and -38.1%, respectively, while the SPY returned +10.2% and +1.7%, respectively.
NCNA support price is $.28 and resistance is $.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NCNA stock will trade within this expected range on the day.